½ÃÀ庸°í¼­
»óǰÄÚµå
1576522

¼¼°èÀÇ ¹«Ç¥Áö °ËÃâ(LFD) ½ÃÀå ±Ô¸ð, Á¡À¯À², ¿¹Ãø ¹× µ¿Ç⠺м® : Á¦Ç°, ±â¼ú, °øÁ¤, ¿ëµµ ¹× ÃÖÁ¾ »ç¿ëÀÚº° - ¿¹Ãø(-2031³â)

Label-free Detection Market Size, Share, Forecast, & Trends Analysis by Product, Technology, Process, Application, End User - Global Forecast to 2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Meticulous Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 320 Pages | ¹è¼Û¾È³» : 5-7ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¹«Ç¥Áö °ËÃâ(LFD) ½ÃÀåÀº 2024-2031³â°£9.8%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î 2031³â±îÁö 44¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ º¸°í¼­´Â ±¤¹üÀ§ÇÑ 2Â÷ ¹× 1Â÷ Á¶»ç, ½ÃÀå ½Ã³ª¸®¿À¿¡ ´ëÇÑ ½ÉÃþ ºÐ¼®, ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, °úÁ¦ ¹× ±âȸ ºÐ¼®À¸·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº Á¦¾à ¹× »ý¸í°øÇÐ ½ÃÀåÀÇ °í¼ºÀå, Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê, ¿¬±¸ °³¹ß ÀÚ±Ý Áõ°¡, ½Å¾à °³¹ß¿¡ ´ëÇÑ Çõ½ÅÀû Á¢±Ù ¹æ½Ä äÅà Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ±×·¯³ª ³ôÀº Àåºñ ºñ¿ë°ú º¹ÀâÇÑ Àåºñ¸¦ ´Ù·ê ¼ö ÀÖ´Â ¼÷·ÃµÈ Àü¹®°¡ÀÇ ºÎÁ·Àº ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ºñÇ¥Áö °ËÃâÀÇ ±â¼ú ¹ßÀü, PoC °Ë»ç¿¡¼­ ºñÇ¥Áö °ËÃâÀÇ Àû¿ë È®´ë, ½ÅÈï±¹¿¡¼­ÀÇ ºñÇ¥Áö °ËÃâÀº ÀÌ ½ÃÀå¿¡¼­ »ç¾÷À» ¿î¿µÇÏ´Â ±â¾÷µé¿¡°Ô ¼ºÀå ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ÀúÁú·® ÀúºÐÀÚ¸¦ ½Ç½Ã°£À¸·Î °ËÃâÇϱâ À§ÇÑ °úÁ¦¿Í ¹Î°¨µµ ¹× ƯÀ̵µÀÇ ÇѰè´Â ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´Â ÁÖ¿ä °úÁ¦ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ÀλçÀÌÆ®

  • °³¿ä
  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • °úÁ¦
  • µ¿Çâ
  • ¿äÀÎ ºÐ¼®
  • ±ÔÁ¦ ºÐ¼®
    • ¹Ì±¹
    • ij³ª´Ù
    • À¯·´
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • Áßµ¿
  • °¡°Ý ºÐ¼®
  • »ç·Ê ¿¬±¸
  • PorterÀÇ Five Forces ºÐ¼®

Á¦5Àå ¹«Ç¥Áö °ËÃâ(LFD) ½ÃÀå Æò°¡ : Á¦Ç° À¯Çüº°

  • °³¿ä
  • ¼Ò¸ðǰ
    • ¹ÙÀÌ¿À¼¾¼­ Ĩ
    • ¸¶ÀÌÅ©·ÎÇ÷¹ÀÌÆ®
    • ŰƮ ¹× ½Ã¾à
  • Àåºñ
    • ±¤ÇÐ ¹ÙÀÌ¿À¼¾¼­
    • ¸¶ÀÌÅ©·Î ¿­·®°è
    • ±âŸ Àåºñ
  • ¼ÒÇÁÆ®¿þ¾î

Á¦6Àå ¹«Ç¥Áö °ËÃâ(LFD) ½ÃÀå Æò°¡ : ±â¼úº°

  • °³¿ä
  • Surface Plasmon Resonance (SPR)
  • Bio-Layer Interferometry (BLI)
  • Isothermal Titration Calorimetry (ITC)
  • Grating-Coupled Interferometry (GCI)
  • Differential scanning calorimetry (DSC)
  • ±âŸ ±â¼ú

Á¦7Àå ¹«Ç¥Áö °ËÃâ(LFD) ½ÃÀå Æò°¡ : ¿ëµµº°

  • °³¿ä
  • Drug Discovery & Development
  • ¹é½Å °³¹ß
  • À¯ÀüÀÚ Ä¡·á °³¹ß
  • »ý¹°ÇÐÀû ¿¬±¸
  • ±âŸ ¿ëµµ

Á¦8Àå ¹«Ç¥Áö °ËÃâ(LFD) ½ÃÀå Æò°¡ : ÇÁ·Î¼¼½ºº°

  • °³¿ä
  • °áÇÕ µ¿ÅÂ
  • È÷Æ® È®ÀÎ
  • ¸®µå »ý¼º
  • ³»Àμº ¼ö¿ëü ŽÁö
  • °áÇÕ ¿­¿ªÇÐ
  • ±âŸ ÇÁ·Î¼¼½º

Á¦9Àå ¹«Ç¥Áö °ËÃâ(LFD) ½ÃÀå Æò°¡ : ÃÖÁ¾»ç¿ëÀÚº°

  • °³¿ä
  • Á¦¾à ±â¾÷ ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • Çмú±â°ü ¹× ¿¬±¸±â°ü
  • CRO

Á¦10Àå ¹«Ç¥Áö °ËÃâ(LFD) ½ÃÀå Æò°¡ : Áö¿ªº°

  • °³¿ä
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ½ºÀ§½º
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦11Àå °æÀï ºÐ¼®

  • °³¿ä
  • ÁÖ¿ä ¼ºÀå Àü·«
  • °æÀï º¥Ä¡¸¶Å·
  • °æÀï ´ë½Ãº¸µå
    • ¾÷°è ¸®´õ
    • ½ÃÀå Â÷º°È­ ¿äÀÎ
    • ¼±±¸ ±â¾÷
    • ½Å±Ô ±â¾÷
  • ÁÖ¿ä ±â¾÷º° ½ÃÀå Á¡À¯À² ºÐ¼®/½ÃÀå ¼øÀ§(2023³â)

Á¦12Àå ±â¾÷ °³¿ä(»ç¾÷ °³¿ä, À繫 °³¿ä, Á¦Ç° Æ÷Æ®Æú¸®¿À, Àü·« Àü°³ »óȲ)

  • Danaher Corporation
  • PerkinElmer, Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • GE HealthCare Technologies, Inc.
  • Thermo Fisher Scientific Inc.
  • Sartorius AG
  • Corning Inc.
  • Horiba, Ltd.
  • Malvern Panalytical Ltd
  • Bruker Corporation

(ÁÖ : ÁÖ¿ä 5°³»çÀÇ SWOT ºÐ¼®À» °ÔÀç)

Á¦13Àå ºÎ·Ï

LSH 24.11.12

Label-free Detection Market Size, Share, Forecast, & Trends Analysis by Product (Biosensor, Microplate, Microcalorimeter), Technology (SPR, BLI), Process (Binding Kinetic, Lead Generation, Hit Confirmation), Application, End User-Global Forecast to 2031

The label-free detection market is projected to reach $4.48 billion by 2031 at a CAGR of 9.8 % from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. This growth is due to high growth in the pharmaceutical & biotechnology market, government initiatives, rising R&D funding, and increasing adoption of innovative approaches in drug discovery. However, the high cost of instruments and shortage of skilled professionals to handle complex equipment restrain the growth of this market.

Furthermore, the technological advancements in label-free detection, growing applications of label-free detection in point-of-care testing, and emerging economies are expected to generate growth opportunities for the players operating in this market. However, the challenges of detecting low-mass small molecules in real time and limited sensitivity & specificity are major challenges impacting market growth.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2021-2024). The key players operating in the label-free detection market are Danaher Corporation (U.S.), PerkinElmer, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), GE HealthCare Technologies, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Sartorius AG (Germany), Corning Inc. (U.S.), Horiba, Ltd. (Japan), Malvern Panalytical Ltd (U.K.), and Bruker Corporation (U.S.).

Based on product type, the market is segmented into consumables, instruments, and software. Among all the instrument types, in 2024, the optical biosensor instruments segment is expected to account for the largest share of 78.4% of the label-free detection instruments market. The large market share of this segment can be attributed to the direct and real-time measurement, in addition to multiplexing capabilities, which increases its adoption.

Among all the technologies studied in this report, in 2024, the Surface Plasmon Resonance (SPR) segment is expected to account for the larger share of the label-free detection market. The large market share of this segment can be attributed to the benefits offered by the SPR technology over the other technologies, such as real-time monitoring, requires minimal amounts of sample for experiments, high sensitivity, and provides quantitative data on binding kinetics, equilibrium constants, association, and dissociation rates, and many more are the factors contributing to the significant market share of this segment.

Among all the applications studied in this report, in 2024, the drug discovery & development segment is expected to account for the largest share of the label-free detection market. Label-free detection techniques offer high-throughput screening of various drug candidates for a wide range of target molecules and offer real-time molecular interactions. This results in improved screening of massive compound databases. The capacity to quickly identify interesting lead compounds is the factor that boosts the demand for label-free detection in drug discovery.

Among all the processes studied in this report, in 2024, the binding kinetics segment is expected to account for the largest share of the label-free detection market. The large market share of this segment can be attributed to the advancements in structural biology and the growing focus on personalized medicine. Further, to ensure efficacy and safety, biologics, including monoclonal antibodies, need to be properly characterized and tested in terms of binding kinetics. Label-free detection techniques provide a non-destructive and label-free method for examining complicated interactions, which makes them an excellent alternative for biological research.

Among all the end users studied in this report, in 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the label-free detection market. The large market share of this segment can be attributed to the technological advancements that have increased the adoption of label-free technologies by the pharmaceutical & biotechnology companies, and product launches to expand the innovative offering.

An in-depth analysis of the geographical scenario of the label-free detection market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of over 43.6% of the label-free detection market. In the region in 2024, the U.S. is expected to account for the largest share of the label-free detection market in North America. The large share of this regional market is attributed to the presence of major label-free detection companies, increasing adoption of innovative approaches in drug discovery, and technological advancements in label-free detection technologies.

Scope of the Report:

Label-free Detection Market Assessment-by Product Type

  • Consumables
    • Biosensor Chips
    • Microplates
    • Kits & Reagents
  • Instruments
    • Optical Biosensor Instruments
    • Microcalorimeters
    • Other Instruments
  • Software

Label-free Detection Market Assessment-by Technology

  • Surface Plasmon Resonance (SPR)
  • Bio-Layer Interferometry (BLI)
  • Isothermal Titration Calorimetry (ITC)
  • Grating-Coupled Interferometry (GCI)
  • Differential scanning calorimetry (DSC)
  • Other Technologies

Note: Other technologies include Optical Waveguide Grating Technology (OWGT), Microscale Thermophoresis (MST), and Electrical Impedance Spectroscopy (EIS).

Label-free Detection Market Assessment-by Application

  • Drug Discovery & Development
  • Vaccine Development
  • Gene Therapy Development
  • Biological Research
  • Other Applications

Note: Other technologies include bioprocessing and impurity testing.

Label-free Detection Market Assessment-by Process

  • Binding Kinetics
  • Hit Confirmation
  • Lead Generation
  • Endogenous Receptor Detection
  • Binding Thermodynamics
  • Other Processes

Note: Other processes include end-point screening & specificity testing and affinity analysis.

Label-free Detection Market Assessment-by End User

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Contract Research Organizations

Label-free Detection Market Assessment-by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K
    • Italy
    • Spain
    • Switzerland
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Rest of Asia-Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition & Scope
  • 1.2. Market Ecosystem
  • 1.3. Currency & Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Process of Data Collection and Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
  • 2.3. Market Sizing and Forecasting
    • 2.3.1. Market Size Estimation Approach
    • 2.3.2. Growth Forecast Approach
  • 2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

  • 4.1. Overview
  • 4.2. Drivers
    • 4.2.1. Rapid Growth in Pharmaceutical and Biotechnology Market
    • 4.2.2. Rising Government Initiatives and Funding for Various R&D Activities
    • 4.2.3. Increasing Adoption of Innovative Approaches in Drug Discovery
    • 4.2.4 Rising Focus on Personalized Medicine
  • 4.3. Restraints
    • 4.3.1. High Cost of Instruments
    • 4.3.2. Shortage of Skilled Professionals to Handle Complex Equipment
  • 4.4. Opportunities
    • 4.4.1. Technological advancements in Label-free Detection
    • 4.4.2. Growing Applications Label-free Detection in Point of Care Testing
    • 4.4.3. Emerging Economies: Asia Pacific and Latin America
  • 4.5. Challenges
    • 4.5.1. Challenges of Detecting Low-mass Small Molecules in Real Time
    • 4.5.2. Limited Sensitivity and Specificity
  • 4.6. Trends
    • 4.6.1. Emergence of Artificial Intelligence (AI) & Machine Learning (ML)
    • 4.6.2. Integration with Microfluidics and Lab-on-a-Chip Platforms
  • 4.7. Factor Analysis
  • 4.8. Regulatory Analysis
    • 4.8.1. U.S.
    • 4.8.2. Canada
    • 4.8.3. Europe
    • 4.8.4. China
    • 4.8.5. Japan
    • 4.8.6. India
    • 4.8.7. Latin America
    • 4.8.8. Middle East
  • 4.9. Pricing Analysis
  • 4.10. Case Studies
  • 4.11. Porter's Five Forces Analysis

5. Label-free Detection Market Assessment-by Product Type

  • 5.1. Overview
  • 5.2. Consumables
    • 5.2.1. Biosensor Chips
    • 5.2.2. Microplates
    • 5.2.3. Kits & Reagents
  • 5.3. Instruments
    • 5.3.1. Optical Biosensor Instruments
    • 5.3.2. Microcalorimeters
    • 5.3.3. Other Instruments
  • 5.4. Software

6. Label-free Detection Market Assessment-by Technology

  • 6.1. Overview
  • 6.2. Surface Plasmon Resonance (SPR)
  • 6.3. Bio-Layer Interferometry (BLI)
  • 6.4. Isothermal Titration Calorimetry (ITC)
  • 6.5. Grating-Coupled Interferometry (GCI)
  • 6.6. Differential scanning calorimetry (DSC)
  • 6.7. Other Technologies

7. Label-free Detection Market Assessment-by Application

  • 7.1. Overview
  • 7.2. Drug Discovery & Development
  • 7.3. Vaccine Development
  • 7.4. Gene Therapy Development
  • 7.5. Biological Research
  • 7.6. Other Applications

8. Label-free Detection Market Assessment-by Process

  • 8.1. Overview
  • 8.2. Binding Kinetics
  • 8.3. Hit Confirmation
  • 8.4. Lead Generation
  • 8.5. Endogenous Receptor Detection
  • 8.6. Binding Thermodynamics
  • 8.7. Other Process

9. Label-free Detection Market Assessment-by End User

  • 9.1. Overview
  • 9.2. Pharmaceutical & Biotechnology Companies
  • 9.3. Academic & Research Institutes
  • 9.4. Contract Research Organizations

10. Label-free Detection Market Assessment-by Geography

  • 10.1. Overview
  • 10.2. North America
    • 10.2.1. U.S.
    • 10.2.2. Canada
  • 10.3. Europe
    • 10.3.1. Germany
    • 10.3.2. France
    • 10.3.3. U.K.
    • 10.3.4. Italy
    • 10.3.5. Spain
    • 10.3.6. Switzerland
    • 10.3.7. Rest of Europe
  • 10.4. Asia-Pacific
    • 10.4.1. Japan
    • 10.4.2. China
    • 10.4.3. India
    • 10.4.4. Rest of Asia-Pacific
  • 10.5. Latin America
  • 10.6. Middle East & Africa

11. Competition Analysis

  • 11.1. Overview
  • 11.2. Key Growth Strategies
  • 11.3. Competitive Benchmarking
  • 11.4. Competitive Dashboard
    • 11.4.1. Industry Leaders
    • 11.4.2. Market Differentiators
    • 11.4.3. Vanguards
    • 11.4.4. Emerging Companies
  • 11.5. Market Share Analysis/Market Rankings, by Key Players (2023)

12. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)

  • 12.1. Danaher Corporation
  • 12.2. PerkinElmer, Inc.
  • 12.3. Agilent Technologies, Inc.
  • 12.4. Bio-Rad Laboratories, Inc.
  • 12.5. GE HealthCare Technologies, Inc.
  • 12.6. Thermo Fisher Scientific Inc.
  • 12.7. Sartorius AG
  • 12.8. Corning Inc.
  • 12.9. Horiba, Ltd.
  • 12.10. Malvern Panalytical Ltd
  • 12.11. Bruker Corporation

(Note: SWOT analysis of the top 5 companies will be provided.)

13. Appendix

  • 13.1. Available Customization
  • 13.2. Related Reports
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦